NCT01845038View on ClinicalTrials.gov

Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

May 31, 2014

Conditions
Glaucoma
Interventions
DRUG

OTX-TPa ~4µg/day over 2 mos. with natural tears drops

OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of \~4µg/day over 2 months. Subjects in this arm will also receive natural tears drops.

DRUG

OTX-TPb ~3µg/day over 3 months with natural tears drops

OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of \~3µg/day over 3 months. Subjects in this arm will also receive natural tears drops.

DRUG

Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug

Timolol Maleate (0.5%) ophthalmic solution dosed twice daily. Subjects in this arm will also have a hydrogel punctum plug without drug placed.

Trial Locations (1)

Unknown

Umhlanga Hospital Medical Centre, Durban

Sponsors
All Listed Sponsors
lead

Ocular Therapeutix, Inc.

INDUSTRY

NCT01845038 - Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma | Biotech Hunter | Biotech Hunter